Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Indivior ( (INDV) ).
On March 12, 2026, Indivior Pharmaceuticals, Inc. announced a proposed private offering of $400 million in convertible senior notes due 2031, with an option for initial purchasers to buy an additional $60 million. The senior unsecured notes, offered to qualified institutional buyers under Rule 144A, will pay semi-annual interest and may be converted into cash and, if applicable, common stock under specified conditions.
Indivior plans to use about $239 million of the proceeds, along with roughly $102 million of existing cash, to repay and terminate its term loan and revolving credit facilities, strengthening its balance sheet. Up to approximately $75 million of the proceeds may fund concurrent share repurchases, a move that could support the company’s stock price and influence the effective conversion price of the notes, with the remaining funds allocated to general corporate purposes.
The most recent analyst rating on (INDV) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
Spark’s Take on INDV Stock
According to Spark, TipRanks’ AI Analyst, INDV is a Neutral.
The score is held back mainly by weaker balance-sheet quality (negative equity) and volatile/negative recent cash flow, despite improving profitability. Offsetting this, the latest earnings call was a positive catalyst with strong 2026 EBITDA and operating cash flow guidance plus a sizable buyback. Technicals are mixed and valuation is relatively high with no dividend support.
To see Spark’s full report on INDV stock, click here.
More about Indivior
Indivior Pharmaceuticals, Inc. is a biopharmaceutical company specializing in long-acting injectable treatments for opioid use disorder, focusing on evidence-based therapies that address addiction as a chronic but treatable brain disease. With more than 25 years in addiction medicine, the company targets patients, healthcare providers, and public health systems seeking long-term recovery solutions for opioid dependence.
Building on its heritage in addiction science, Indivior positions itself as a leader in the opioid use disorder treatment market by combining pharmacological innovation with a strong public health mission. Its strategy emphasizes compassion, integrity, and collaboration with patients and communities to expand access to treatment and support sustained recovery outcomes.
Average Trading Volume: 2,319,959
Technical Sentiment Signal: Buy
Current Market Cap: $4.11B
For detailed information about INDV stock, go to TipRanks’ Stock Analysis page.